BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26240484)

  • 1. Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder.
    Lim SD; Cho YM; Choi GS; Park HK; Paick SH; Kim WY; Kim SN; Yoon G
    J Korean Med Sci; 2015 Aug; 30(8):1068-77. PubMed ID: 26240484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
    Krüger S; Lange I; Kausch I; Feller AC
    Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques.
    Nedjadi T; Al-Maghrabi J; Assidi M; Dallol A; Al-Kattabi H; Chaudhary A; Al-Sayyad A; Al-Ammari A; Abuzenadah A; Buhmeida A; Al-Qahtani M
    BMC Cancer; 2016 Aug; 16():653. PubMed ID: 27539085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
    Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
    Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
    Chen PC; Yu HJ; Chang YH; Pan CC
    J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
    Nonomura N; Nakai Y; Nakayama M; Inoue H; Nishimura K; Hatanaka E; Arima R; Kishimoto T; Miki T; Kuroda H; Okuyama A
    Int J Clin Oncol; 2006 Aug; 11(4):297-302. PubMed ID: 16937303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder.
    Kim B; Kim G; Song B; Lee C; Park JH; Moon KC
    Dis Markers; 2016; 2016():8463731. PubMed ID: 27034533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substaging of pT1 Urothelial Bladder Carcinoma Predicts Tumor Progression and Overall Survival.
    Grobet-Jeandin E; Wirth GJ; Benamran D; Dupont A; Tille JC; Iselin CE
    Urol Int; 2022; 106(2):130-137. PubMed ID: 33965961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Application of Different Substaging Techniques for Non-Muscle Invasive Urothelial Carcinoma.
    Eldin ME; Makboul R; Behnsawy HM; Abdelkawi IF; Moeen AM; Faddan AA; Gadelmoula M; Shahat AA; Abdel-Aziz MA; Hafez MM; Hameed DA
    Pathol Oncol Res; 2020 Jul; 26(3):1823-1831. PubMed ID: 31754921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
    Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
    Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression.
    Lawless M; Gulati R; Tretiakova M
    Histopathology; 2017 Sep; 71(3):406-414. PubMed ID: 28470753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series.
    Bertz S; Denzinger S; Otto W; Wieland WF; Stoehr R; Hofstaedter F; Hartmann A
    Histopathology; 2011 Oct; 59(4):722-32. PubMed ID: 22014053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
    Abdelrahman AE; Rashed HE; Elkady E; Elsebai EA; El-Azony A; Matar I
    Ann Diagn Pathol; 2019 Apr; 39():42-52. PubMed ID: 30684846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladder.
    Hori S; Miyake M; Onishi S; Tatsumi Y; Morizawa Y; Nakai Y; Anai S; Tanaka N; Fujimoto K
    Oncol Rep; 2016 Oct; 36(4):2117-25. PubMed ID: 27573985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
    March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM
    Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
    Kiyoshima K; Oda Y; Kinukawa N; Naito S; Tsuneyoshi M
    Hum Pathol; 2005 May; 36(5):522-30. PubMed ID: 15948119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.